For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

News

CAP Today Interview with Dr. Alain C. Borczuk

Don't miss the front page CAP Today interview with Alain C. Borczuk, M.D., Chief of Thoracic Pathology at Weill Cornell Medicine, on his work to understand lung injury patterns in COVID-19 patients.

Read the full article here.

Dr. Domenick Falcone Appointed Assistant Dean for Foundation Curriculum

Domenick Falcone, PhD
Professor of Pathology and Laboratory Medicine

Please join us in congratulating Domenick Falcone, PhD on becoming the inaugural Assistant Dean for Foundation Curriculum.

Dr. Domenick Falcone, Professor of Pathology and Laboratory Medicine and currently Co-Director of the first-year foundational Essential Principles of Medicine (EPOM) course and Leader of the Injury, Infection, Immunity and Repair unit of EPOM, will become the inaugural Assistant Dean for Foundational Curriculum. Dr. Falcone has shown true dedication and innovation in medical education for nearly forty years. He has been a key contributor to curricular design and reform, and he has consistently taught in the foundational curriculum where he has received many honors recognizing his exceptional teaching skills and leadership in medical education. He has also been the holder of Education Scholar Awards, including the Thomas H. Meikle Chair of Medical Education and the Gary M. Sumers Educational Scholar Award. 

So proud to have him on our faculty!!!

Enzyme Blocks Metabolic Processes that Spur Rapid Growth and Spread of Liver Cancer

Jorge Moscat, PhD
Professor of Pathology and Laboratory Medicine


An enzyme has been discovered to play a critical role in blocking the metabolic processes that contribute to the rapid growth and spread of liver cancer, according to a new study by Weill Cornell Medicine researchers, a finding that could spur development of new therapies for a condition that has been historically difficult to treat.

The study, published June 25 in Cancer Celldemonstrates that low levels of the enzyme protein kinase C (PKC) λ/i in mice and human liver tumors are associated with the aggressive form of cancer, and that the protein acts as a tumor suppressor. The researchers also describe the metabolic pathways that PKC λ/i directly blocks to inhibit tumors.

“Treatments for liver cancer are not particularly effective as compared with other types of cancer,” said lead study author Dr. Jorge Moscat, a professor of pathology and laboratory Medicine at Weill Cornell Medicine. “It’s a devastating disease.”

About 27,000 people in the United States die from liver cancer each year.The cancer is associated with nonalcoholic fatty livery disease (NAFLD), a condition in which too much fat is stored in the liver. NAFLD, which is on the rise in the U.S., is in turn linked to more common diseases such as obesity, diabetes and metabolic syndrome.

Weill Cornell Medicine Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464 Fax: (212) 746-8192